Turkish Journal of Urology
Original Article

Efficacy and tolerability of Serenoa repens extract (Prostagood®) in patients wlth lower urinary tract symptoms due to symptomatic benign prostatic hyperplasia


Atatürk Research and Training Hospital, First Urology Clinic, Ankara, Turkey


Numune Research and Training Hospital, Third Urology Clinic, Ankara, Turkey


Haydarpaşa Research and Training Hospital, First Urology Clinic, İstanbul, Turkey


Department of 2nd Urology, Ministry of Health, Education and Research Hospital of Göztepe, İstanbul

Turk J Urol 2009; 35: 347-354
Read: 839 Downloads: 480 Published: 25 July 2019


Objective: The aim of this study was to investigate the efficacy and safety of Serenoa repens extract (Prostagood®)in the treatment of lower urinary tract (LUT) symptoms due to benign prostatic hyperplasia (BPH).


Materials and methods: A prospective, open-labelled, multicenter study was designed including 106 patients (mean age 59.2±7.1) with LUT symptoms due to BPH [mean International Prostate Symptom Score (I-PSS) 18.5±5.0]. Following a 2 week run-in period of no treatment, patients received Prostagood® (160 mg Serenoa repens extract/softgel twice daily) for 12 weeks. 


Results: Serenoa repens extract treatment caused a significant improvement in the I-PSS score (12.1±6.7 vs. 18.4±4.9, p<0.001), the SF-36 score (74.1±15.9 vs. 76.9±13.4, p=0.021), and the life quality index score of the I-PSS (median 3 vs. 4, p<0.001). Maximum urine flow (Qmax) increased significantly from 9.7±3.0 mL/sec to 10.9±4.4 mL/secec (p=0.003) with treatment, while no significant change was observed in the urine flow (Qmean) (4.8±1.7 mL/sec vs. 5.1±1.9 mL/sec, p=0.178), micturition volume and duration (273.1 ±138.5 mL vs. 282.4±144.3 mL, p=0.424 and 65.4±34.5 sec vs. 67.4±38.2 sec, p=0.580 respectively), peak flow time (13.3±15.6 sec vs.14.4±15.4 sec, p=0.447), prostate volume (36.9±16.9 mL vs.38.8±19.0 mL, p=0.173) and postvoid residual urine volume (63.3±38.0 mL vs. 71.3±59.3 mL, p=0.141). There was no differences in prostate specific antigen (PSA) between baseline and end of study (2.2±2.2 ng/dL vs. 2.1±2.2 ng/dL, p=0.545).


Conclusion: Serenoa repens extract decreases LUT symptoms due to BPH, and improves patients’ quality of life. It is efficacious according to some of the uroflowmetric parameters and it is well tolerated.

EISSN 2149-3057